ClinConnect ClinConnect Logo
Search / Trial NCT00000937

Study and Treatment of Post Lyme Disease (STOP-LD)

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of July 01, 2025

Completed

Keywords

ClinConnect Summary

You will be assigned randomly (like tossing a coin) to receive either antibiotics or a placebo (sugar pill). Neither you nor your doctor will know which you are receiving. You will learn to give yourself the injection, and you will remain on your study drug for 28 days. A home health care nurse will visit you twice a week to check the injection site, and at weeks 1 and 3 the nurse will draw blood for laboratory tests. At months 1 and 6, you will be examined to see if you have fewer chronic fatigue symptoms after the antibiotics. This will include a fatigue questionnaire, a test of your ment...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • You may be eligible for this study if you:
  • Are between 18 and 65 years of age.
  • Are a resident of Long Island or greater NY metropolitan area.
  • Are fluent in English.
  • Have a history of Lyme Disease.
  • Have completed antibiotic treatment for Lyme Disease 6 or more months before starting the study.
  • Have severe fatigue.
  • Are not pregnant or planning to be pregnant.
  • Exclusion Criteria:
  • You will not be eligible for this study if you:
  • Have or have had major medical, neurologic, or psychiatric disorder.
  • Have had prior chronic pain, fatigue, or recurrent severe headaches before the onset of Lyme Disease.
  • Have had Fibromyalgia Syndrome.
  • Have a history of sleep apnea, narcolepsy, or other serious sleep disorder.
  • Have a learning disability.
  • Have had head trauma requiring hospitalization.
  • Have symptomatic gallbladder disease.
  • Are anemic.
  • Abuse alcohol or illicit drugs.
  • Have been treated with another antimicrobial agent for Lyme Disease within 6 months of study.
  • Need to be receiving systemic steroid therapy during drug administration and follow-up.
  • Have used benzodiazepines within 1 month of study entry.
  • Are allergic to Beta lactams (a class of antibiotics).

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Stony Brook, New York, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials